We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+43.89%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$2.32B
AUM Growth
+$601M
Cap. Flow
+$106M
Cap. Flow %
4.57%
Top 10 Hldgs %
72.02%
Holding
31
New
6
Increased
4
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$55.6M
2
DTIL icon
Precision BioSciences
DTIL
+$32.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$30.6M
4
IFRX icon
InflaRx
IFRX
+$27M
5
ALEC icon
Alector
ALEC
+$18.9M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$43.1M
2
ARVN icon
Arvinas
ARVN
+$17.7M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$17.1M
4
ASND icon
Ascendis Pharma A/S
ASND
+$9.47M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALEC icon
26
Alector
ALEC
$227M
$18.7M 0.81%
+1,000,000
New +$18.9M
SWAV
27
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$16.6M 0.72%
+495,608
New +$16.5M
SCPH
28
DELISTED
scPharmaceuticals
SCPH
$8.57M 0.37%
2,857,143
– –
GTHX
29
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$6.03M 0.26%
+363,051
New +$6.89M
TARA icon
30
Protara Therapeutics
TARA
$222M
– –
-33,437
Closed -$3.04M
IMMU
31
DELISTED
Immunomedics Inc
IMMU
– –
-3,021,466
Closed -$43.1M
1
2

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, RA Capital Management held 31 positions worth $2.32B, up 35% from $1.72B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

RA Capital Management deployed $106M of net new capital in Q1 2019, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was Sage Therapeutics: 384,001 shares worth $61.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Arvinas, an estimated $17.7M trimmed.

  • RA Capital Management's largest Q1 2019 buy was Sage Therapeutics: 384,001 shares worth $61.1M.
  • RA Capital Management added most to InflaRx in Q1 2019, an estimated $27M increase.
  • RA Capital Management's biggest Q1 2019 reduction was Arvinas, cutting an estimated $17.7M.
  • RA Capital Management fully exited Immunomedics Inc in Q1 2019, selling an estimated $43.1M.
  • RA Capital Management's ten largest holdings make up 72% of its $2.32B portfolio in Q1 2019.
  • RA Capital Management opened 6 new positions and closed 2 in Q1 2019.
  • RA Capital Management's portfolio value rose 35% quarter-over-quarter to $2.32B.

Based on RA Capital Management's 13F filing for Q1 2019, filed 15 May 2019.